Select Page

The Infinium Global Research analyzes the Benign Prostatic Hyperplasia Treatment Market over the period of 2019 to 2025. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in global benign prostatic hyperplasia treatment market. It will help a lot of decision makers to develop strategies and find new opportunities in the global markets of benign prostatic hyperplasia treatment. The report covers market changing aspects including drivers, restraints, opportunities, and trends expected to encouragement the expansion of the benign prostatic hyperplasia treatment market during the period. The global benign prostatic hyperplasia treatment market is projected to grow at a CAGR of 8.3% over the forecast period of 2019-2025.

“We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2020-2026.” 

The Section on the Impact of COVID-19 on this Market is Included in the Report for Free. To Know More Request Sample of this Report:   https://www.infiniumglobalresearch.com/reports/sample-request/15069

Benign prostatic hyperplasia (BPH) is a medical condition involving the expansion of the prostate gland and is highly prevalent in males. It is a non-cancerous growth of the prostate gland originating from the uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, weak urinary system, and inability to empty the urinary bladder.

The growing occurrence of benign prostatic hyperplasia coupled with the growing risk factors are the major factors that drive the growth of the benign prostatic hyperplasia treatment market across the globe. Furthermore, the increase in the male geriatric population is the other key factor that augments market growth. According to the United States Census Bureau in 2018, the population of people aged 65 and above in the United States is likely to increase drastically between 2016 and 2060. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million, out of the total population. However, the high cost of benign prostatic hyperplasia treatment is expected to may restrain the growth of the market. Moreover, the growing preference for in-office based minimally invasive surgical techniques creates an opportunity for the growth of the benign prostatic hyperplasia treatment market in the next few years.

North America is Expected to Dominate the Benign Prostatic Hyperplasia Treatment Market

In terms of region, North America is expected to dominate the benign prostatic hyperplasia treatment market during the forecast period. This is attributed to factors such as the geriatric population, growing incidences of benign prostatic hyperplasia, and highly structured healthcare industry in the region. Furthermore, increasing the aging population of the United States coupled with a rise in diabetes and obesity is poised to surge the occurrence of benign prostatic hyperplasia and lower urinary tract conditions in the region. Moreover, the Asia Pacific region is projected to grow at a faster rate over the forecast period due to the high population base, growing disposable income, and greater patient awareness about the benign prostatic hyperplasia treatment market.

Segment Covered

The report on the global benign prostatic hyperplasia treatment market covers segments such as therapeutic class, therapy, and end user. On the basis of therapeutic class, the sub-markets include alpha-blocker, phosphodiesterase-5 inhibitor, 5-alpha reductase inhibitor, and other therapeutic class. On the basis of therapy, the sub-markets include mono drug therapy, and combination drug therapy. On the basis of end user, the sub-markets include hospitals, specialty clinics, ambulatory surgical centers, and other end users.

Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-benign-prostatic-hyperplasia-treatment-market

Companies Profiled:

The report provides profiles of the companies in the market such as Allergan plc, Eli Lilly and Company, Pfizer, Inc., Astellas Pharma, Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Sanofi, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.

Reasons to Buy this Report: 

=> Comprehensive analysis of global as well as regional markets of the benign prostatic hyperplasia treatment.

=> Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.

=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.   

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.